Diagnostic Accuracy in Sepsis Act of 2025
- Sponsor
- Rep. Kelly, Mike [R-PA-16]
- Committees
- Ways and Means Committee (primary)
- Last action
- Sep 10, 2025
Bottom line
This bill aims to improve patient safety and diagnostic accuracy by penalizing hospitals for high rates of blood culture contamination under Medicare's hospital-acquired conditions program.
What it actually does
This bill amends Title XVIII of the Social Security Act to designate 'blood culture contamination' as a hospital-acquired condition (HAC) under the Medicare program, effective for discharges occurring during fiscal year 2026 and subsequent fiscal years. It mandates that the Secretary of Health and Human Services establish a measure for this condition, setting a target rate of no more than 1 percent for subsection (d) hospitals. Hospitals exceeding this threshold could face reduced Medicare payments.
Proponents argue
Supporters argue that including blood culture contamination as an HAC incentivizes hospitals to improve their practices, leading to better patient outcomes, more accurate diagnoses (especially for sepsis), and reduced healthcare costs associated with misdiagnosis or unnecessary treatment. It promotes accountability and quality of care by encouraging adherence to best practices in blood collection.
Opponents contend
Opponents might argue that this adds another administrative burden and potential financial penalty to hospitals, which are already facing significant challenges. They might contend that a 1% threshold is arbitrary or difficult to achieve consistently across all hospital settings, potentially leading to unintended consequences like under-reporting or diverting resources from other critical quality improvements.
The bill is very short and straightforward, making it highly accessible for a quick review by any interested reader.
Section 2, amending Section 1886(p) of the Social Security Act
Inclusion of Blood Culture Contamination as a Hospital-Acquired Condition under Medicare
This provision modifies existing Medicare law to classify blood culture contamination as a 'hospital-acquired condition' (HAC) starting in fiscal year 2026. It directs the Secretary of Health and Human Services to create a standard for measuring this contamination, specifically stating that the rate should not exceed 1 percent in hospitals. Hospitals that fail to meet this standard may face reduced Medicare payments, similar to other HACs, thereby incentivizing improved blood collection practices and diagnostic accuracy.
Supporters argue
Supporters argue that this provision directly addresses a critical issue in patient care. Blood culture contamination leads to false positive results, which can cause patients to receive unnecessary antibiotics, undergo additional invasive procedures, and experience longer hospital stays, all while delaying the correct diagnosis. By making it an HAC, hospitals will be incentivized to adopt best practices for blood collection, thereby improving diagnostic accuracy, reducing healthcare costs, and enhancing patient safety, especially in the context of sepsis diagnosis.
Critics contend
Critics might contend that while the goal is laudable, implementing a strict 1% threshold for blood culture contamination could place undue burden on hospitals, particularly those serving complex patient populations or with limited resources. They might argue that achieving such a low rate consistently is challenging and could lead to hospitals focusing disproportionately on this metric at the expense of other important quality initiatives, or even disincentivizing necessary blood cultures in difficult cases to avoid penalties.
Tradeoffs
The bill balances the desire for improved diagnostic accuracy and patient safety against the potential for increased administrative burden and financial penalties for hospitals. It aims to drive quality improvement but risks creating unintended consequences if the target is deemed too aggressive or if hospitals struggle with implementation. There's a tension between setting an ambitious quality standard and ensuring feasibility across diverse healthcare settings.